INT77417

Context Info Confidence 0.42 First Reported 1998 Last Reported 2010 Negated 0 Speculated 0 Reported most in Body Documents 3 Total Number 3 Disease Relevance 0.71 Pain Relevance 0.16

nucleus (ZGLP1)

ZGLP1 (Homo sapiens)

Pain Link Frequency Relevance Heat agonist 4 75.12 adenocard 1 67.84 Paracetamol 3 53.76 nud 4 40.96 cytokine 2 17.44 Bioavailability 3 5.00 Parenteral administration 2 5.00 pruritus 2 5.00 tolerance 2 5.00 headache 2 5.00

Disease Link Frequency Relevance Heat Obesity 17 90.64 Diabetes Mellitus 125 89.32 Monsters 2 52.24 Insulin Resistance 11 51.00 Disease 11 43.44 Dyspepsia 4 40.96 Weight Gain 9 35.48 Apoptosis 5 30.00 Overnutrition 13 26.28 Death 1 15.68

Sentences Mentioned In

Key:

Protein

Mutation

Event

Anatomy

Negation

Speculation

Pain term

Disease term

GLP-1 has been shown to have an incretin effect and inhibits gastrointestinal motility in humans.

Negative_regulation (inhibits) of GLP-1

1) Confidence 0.42 Published 1998 Journal Am. J. Clin. Nutr. Section Abstract Doc Link 9734726 Disease Relevance 0.24 Pain Relevance 0.05

Liraglutide (Victoza®; Novo Nordisk), an analog of human GLP-1, is a fatty acid derivative of GLP-1 that has been approved for clinical use more recently.

Negative_regulation (derivative) of GLP-1

2) Confidence 0.29 Published 2010 Journal Patient Prefer Adherence Section Body Doc Link PMC2943223 Disease Relevance 0.26 Pain Relevance 0

GLP-1 receptors are G-protein coupled receptor (GPCR) present on the islet beta-cells.

Negative_regulation (receptors) of GLP-1

3) Confidence 0.12 Published 2010 Journal Indian Journal of Pharmaceutical Sciences Section Body Doc Link PMC2883206 Disease Relevance 0.22 Pain Relevance 0.10

General Comments

This test has worked.